2- ( diethylamino-2-ethyl ) 9-hydroxyellipticinium-chloride , hcl ( dhe ) , a new congener of the antitumor agent elliptinium acetate ( celiptium ) ( nmhe ) , has recently been selected for phase i clinical trials .
C0100593
elliptinium acetate
C0046355
celiptium